05.05.2010 • NewsPfizerQ1 2010Wyeth

Pfizer Profit Beats, Forecast Unhurt by Reform

Pfizer reported better-than-expected first-quarter profit and revenue, and reaffirmed its full-year earnings forecast despite costs of recently approved U.S. healthcare reforms.

The world's biggest drugmaker, which in October completed its $67 billion purchase of U.S. rival Wyeth, earned $2.03 billion, or 25 cents per share in the quarter. That compared with $2.73 billion, or 40 cents per share, in the year-earlier period.

Excluding special items, Pfizer earned 60 cents per share. Analysts on average expected 53 cents per share, according to Thomson Reuters I/B/E/S.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.